News
ICViewExpert PerspectivesMedical World NewsPathogen PlaybookVideosWebinars
Conference CoverageConference ListingAPIC Chapters
Infection Control TodaySupplements And Featured Publications
CME/CEEditorial Advisory BoardJob BoardPartnersSponsoredWhitepapers
Subscribe
Educator of the Year Official Rules2024 Educator of the Year Winner2023 Educator of the Year WinnerEducator of the Year
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • IC Trends
  • Bug of the Month
  • Featured Articles
  • Featured Columns
  • Pathogen Playbook
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
    • News
    • Subscribe
Advertisement

Imatinib (Gleevec) Has Activity in AIDS-related Kaposi's Sarcoma

December 15, 2004
Article

ALEXANDRIA, Va. -- A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within four weeks in some patients. The study was published November 30 in the Journal of Clinical Oncology (JCO).

 

"Imatinib is a targeted therapy originally shown to be effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. This study and others are showing that the drug is also active in other cancers that express some of the same proteins," said Henry B. Koon, MD, instructor of medicine, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and lead author of the study. "Studies like this one represent an exciting time in oncology, when our understanding of the development of diseases like KS coincide with the availability of effective treatments. Further research on imatinib in KS patients will be needed to determine appropriate dosing schedules."

 

Kaposi's sarcoma is an AIDS-defining illness characterized by soft purplish lesions on the skin, mucous membranes, and internal organs. Although the incidence of KS has declined dramatically in the developed world since the advent of highly active antiretroviral therapies (HAART), it remains a significant cause of morbidity and mortality for AIDS patients in the United States and a major cause of mortality in the third world, given the limited number of effective treatments for KS.

 

Researchers examined the response of Kaposi's sarcoma to imatinib, a drug known to inhibit the PDGF-R and/or c-kit pathways that are responsible for the growth of other cancers, such as chronic myelogenous leukemia, gastrointestinal stromal tumors (GIST), and bone sarcomas of the head and neck. Given that PDGF-R and c-kit also play a role in the development of KS, researchers theorized that imatinib may be an effective strategy for treating the disease.

 

Researchers from Beth Israel Deaconess Medical Center in Boston administered 300 mg of imatinib twice daily for a minimum of four weeks to ten male patients with KS, which had progressed despite chemotherapy and/or HAART. Half of the study participants demonstrated partial regression of lesions, and in the remaining five patients, disease stabilized and they were no longer developing new lesions after four weeks. Biopsies of patients' tumors demonstrated that these responses correlated with inhibition of the target proteins by imatinib.

Researchers reported that the dose of imatinib administered to patients was poorly tolerated and caused severe side effects, including diarrhea, requiring a dose reduction to 200 mg twice daily for all patients by the fourth week of treatment. Researchers noted that the incidence of diarrhea was higher than in trials of patients with chronic myeloid leukemia receiving the same dose. Although the reason for the high degree of toxicity is unclear, researchers speculate that imatinib may interact with the medications involved in the HAART regimen, which can also cause diarrhea.

 

Researchers noted that once patients develop KS, it tends to recur after therapy, and most patients have multiple relapses followed by multiple therapies. Given this, they underscored the need to develop less toxic dosing schedules -- either by administering imatinib at a lower dose for a longer duration, or at a higher dose for a shorter period -- to limit the severity of side effects.

 

Results of this study were used to develop a phase II trial that is currently underway involving 25 KS patients receiving 200 mg of imatinib twice daily. The trial, which is being conducted by the AIDS Malignancy Clinical Trial Consortium at the National Cancer Institute, will more closely examine the ways in which imatinib causes severe toxicity in KS patients on HAART.

 

Reference:

"Imatinib Induced Regression of AIDS-Related Kaposi's Sarcoma." Henry B. Koon, et al, Beth Israel Deaconess Medical Center, Boston.

 

Source: American Society Of Clinical Oncology

Recent Videos
Jordan Bastian, MPH, CIC, at APIC25
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Related Content

CDC  (Adobe Stock, unknown)

CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures

Infection Control Today® Editorial Staff
July 11th 2025
Article

With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.


IP LifeLine from Infection Control Today

IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists

Brenna Doran, PhD, MA, ACC, CIC
July 11th 2025
Article

Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.


Washing hands at a sink  (Adobe Stock 1298928756)

A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings

Kerri Simone, MPH, CIC;Alexander O’Flaherty Linehan ;Will Zacamy
July 9th 2025
Article

Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.


Cori L. Ofstead, MSPH; Brandon M. Gantt, MHA, CRCST, CHL, CER, LSSGBH; and Jill E. Holdsworth, MS, CIC, FAPIC, NREMT, CRCST, CHL

Lumens 2.0 Study Results: Borescopes Reveal Hidden Challenges of Cleaning Lumened Surgical Instruments

Tori Whitacre Martonicz
July 8th 2025
Article

A groundbreaking study presented at HSPA25 and APIC25 exposed hidden contamination lurking inside orthopedic and neurosurgical instruments—even after cleaning. The Lumens 2.0 research highlights why infection prevention must look deeper than surface-level protocols.


Certification Board of Infection Control and Epidemiology (CBIC) logo  (Logo credit to CBIC)

CBIC Seeks Input for Job Analysis Survey for the a-IPC Certification

Infection Control Today® Editorial Staff
July 8th 2025
Article

The Certification Board of Infection Control and Epidemiology (CBIC) is calling on infection prevention professionals to help shape the future of the a-IPC exam through a vital new job analysis survey.


The Clean Bite

Why You Should Always Ask About Sterilization at the Dentist

Sherrie Busby, EDDA, CDSO, CDIPC
July 7th 2025
Article

Patients rarely question sterilization protocols at the dentist, yet it is essential for safety. The Clean Bite explores why asking matters, what to look for, and how to start the conversation confidently.

Related Content

CDC  (Adobe Stock, unknown)

CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures

Infection Control Today® Editorial Staff
July 11th 2025
Article

With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.


IP LifeLine from Infection Control Today

IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists

Brenna Doran, PhD, MA, ACC, CIC
July 11th 2025
Article

Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.


Washing hands at a sink  (Adobe Stock 1298928756)

A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings

Kerri Simone, MPH, CIC;Alexander O’Flaherty Linehan ;Will Zacamy
July 9th 2025
Article

Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.


Cori L. Ofstead, MSPH; Brandon M. Gantt, MHA, CRCST, CHL, CER, LSSGBH; and Jill E. Holdsworth, MS, CIC, FAPIC, NREMT, CRCST, CHL

Lumens 2.0 Study Results: Borescopes Reveal Hidden Challenges of Cleaning Lumened Surgical Instruments

Tori Whitacre Martonicz
July 8th 2025
Article

A groundbreaking study presented at HSPA25 and APIC25 exposed hidden contamination lurking inside orthopedic and neurosurgical instruments—even after cleaning. The Lumens 2.0 research highlights why infection prevention must look deeper than surface-level protocols.


Certification Board of Infection Control and Epidemiology (CBIC) logo  (Logo credit to CBIC)

CBIC Seeks Input for Job Analysis Survey for the a-IPC Certification

Infection Control Today® Editorial Staff
July 8th 2025
Article

The Certification Board of Infection Control and Epidemiology (CBIC) is calling on infection prevention professionals to help shape the future of the a-IPC exam through a vital new job analysis survey.


The Clean Bite

Why You Should Always Ask About Sterilization at the Dentist

Sherrie Busby, EDDA, CDSO, CDIPC
July 7th 2025
Article

Patients rarely question sterilization protocols at the dentist, yet it is essential for safety. The Clean Bite explores why asking matters, what to look for, and how to start the conversation confidently.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News